The Involvement of WDHD1 in the Occurrence of Esophageal Cancer as a Downstream Target of PI3K/AKT Pathway

4Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Esophageal cancer is one of the most common malignant tumors in the world, which is characterized by high incidence, strong invasiveness, high mortality, and poor prognosis. At present, the therapies include surgery, endoscopic resection, radiotherapy and chemotherapy, targeted therapy, and immunotherapy. The five-year survival rate of esophageal cancer has not been significantly improved, although the medical level has been continuously improved and the management and application of different therapies have been improved day by day. At present, an abnormal gene expression is still regarded as an important factor in the occurrence and development of esophageal cancer. WD repeat and HMG-box DNA binding protein 1(WDHD1), as a key gene, plays an important role in the occurrence of esophageal cancer. It is known that the protein encoded by WDHD1 is the downstream target of the PI3K/AKT pathway. When PI3Ks is activated by extracellular signals, PI(4,5)P2 on the inner side of the plasma membrane will be converted into PI(3,4,5)P3. Then, PI(3,4,5)P3 can be converted into PI(3,4)P2,PI(4)P and PI(3)P by dephosphorylation of some regulatory factors. PI(3,4,5)P3 recruited AKT to the plasma membrane and combined with its pH domain, resulting in conformational change of AKT. Subsequently, AKT was completely activated by PDK1 and PDK2 and begins to move to the cytoplasm and nucleus. In this process, AKT continuously phosphorylates downstream substrates. WDHD1, as a downstream target of AKT, is also phosphorylated and induces DNA replication. Besides the abnormal regulation of cells by other downstream targets of AKT, it also becomes a potential pathway that may eventually lead to the occurrence of esophageal cancer.

References Powered by Scopus

Targeting PI3K in cancer: Mechanisms and advances in clinical trials

1107Citations
N/AReaders
Get full text

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

771Citations
N/AReaders
Get full text

Esophageal cancer: Risk factors, genetic association, and treatment

591Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents

41Citations
N/AReaders
Get full text

Integrative bioinformatics analysis of WDHD1: a potential biomarker for pan-cancer prognosis, diagnosis, and immunotherapy

4Citations
N/AReaders
Get full text

WD Repeat and HMG Box DNA Binding Protein 1: An Oncoprotein at the Hub of Tumorigenesis and a Novel Therapeutic Target

4Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Xian, Q., & Zhu, D. (2022). The Involvement of WDHD1 in the Occurrence of Esophageal Cancer as a Downstream Target of PI3K/AKT Pathway. Journal of Oncology. Hindawi Limited. https://doi.org/10.1155/2022/5871188

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

50%

Lecturer / Post doc 1

25%

Researcher 1

25%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 3

75%

Biochemistry, Genetics and Molecular Bi... 1

25%

Save time finding and organizing research with Mendeley

Sign up for free